Inventor · disambiguated record
Jaikrishna Patel
Also filed as: PATEL JAIKRISHNA
7 granted patents·14 pending applications·13 citations·filing 2002–2025
80Inventor score
Top patents by PatentIndex Score
21 records- 0193US11793807B2Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Oct 24, 2023·4 cites·20 claims
- 0291US11969422B2Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Apr 30, 2024·3 cites·18 claims
- 0391US11730733B2Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Aug 22, 2023·2 cites·11 claims
- 0486US12076318B2Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Granted Sep 3, 2024·1 cites·18 claims
- 0582US12318382B2Methods of treating rheumatic diseases using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Jun 3, 2025·3 cites·11 claims
- 0678US12502389B2Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Dec 23, 2025·0 cites·20 claims
- 0778US12233058B2Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Feb 25, 2025·0 cites·9 claims
- 0872US2024245678A1Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0972US2024374584A1Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1063US2025152581A1Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1158US2004180937A1Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dioneSMITHKLINE BEECHAM PLC·Filed 2004·Application pending·0 cites
- 1257US2025235447A1Methods for treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1357US2004082621A1Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dioneSMITHKLINE BEECHAM PLC·Filed 2003·Application pending·0 cites
- 1455US2003187030A1Composition comprising 5-[4-[2-(N-methyl-N-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dioneSMITHKLINE BEECHAM PLC·Filed 2003·Application pending·0 cites
- 1555US2024082242A1Combination therapiesIMBRIA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1649US2021401833A1Modified release formulations of modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1748US2023210845A1Dosing methods for treatment of cardiovascular conditionsIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1846US2021346329A1Tca cycle intermediates and methods of use thereofIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1945US2002177612A1Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dioneSMITHKLINE BEECHAM P I C·Filed 2002·Application pending·0 cites
- 2044US2022249463A1Methods of altering cardiac remodeling using compounds that promote glucose oxidationIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2143US2022168431A1Methods of treating cancer using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jaikrishna Patel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →